Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1151173.RADaYTCO-_Rsq7xNspSDthujUhthxesfU4kVpz0H6_Xv4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1151173.RADaYTCO-_Rsq7xNspSDthujUhthxesfU4kVpz0H6_Xv4130_assertion type Assertion NP1151173.RADaYTCO-_Rsq7xNspSDthujUhthxesfU4kVpz0H6_Xv4130_head.
- NP1151173.RADaYTCO-_Rsq7xNspSDthujUhthxesfU4kVpz0H6_Xv4130_assertion description "[Our results suggest that patients with HER2(+) breast cancer may benefit from anti-TBK1/IKK? plus anti-HER2 combination therapies and establish conditions that can be used to screen for additional TIC-specific inhibitors of HER2(+) breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1151173.RADaYTCO-_Rsq7xNspSDthujUhthxesfU4kVpz0H6_Xv4130_provenance.
- NP1151173.RADaYTCO-_Rsq7xNspSDthujUhthxesfU4kVpz0H6_Xv4130_assertion evidence source_evidence_literature NP1151173.RADaYTCO-_Rsq7xNspSDthujUhthxesfU4kVpz0H6_Xv4130_provenance.
- NP1151173.RADaYTCO-_Rsq7xNspSDthujUhthxesfU4kVpz0H6_Xv4130_assertion SIO_000772 24487029 NP1151173.RADaYTCO-_Rsq7xNspSDthujUhthxesfU4kVpz0H6_Xv4130_provenance.
- NP1151173.RADaYTCO-_Rsq7xNspSDthujUhthxesfU4kVpz0H6_Xv4130_assertion wasDerivedFrom befree-2016 NP1151173.RADaYTCO-_Rsq7xNspSDthujUhthxesfU4kVpz0H6_Xv4130_provenance.
- NP1151173.RADaYTCO-_Rsq7xNspSDthujUhthxesfU4kVpz0H6_Xv4130_assertion wasGeneratedBy ECO_0000203 NP1151173.RADaYTCO-_Rsq7xNspSDthujUhthxesfU4kVpz0H6_Xv4130_provenance.